Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Apply filters
Showing 151 to 175 of 392
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]
Technology appraisal guidance
TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238
Technology appraisal guidance
TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237
Technology appraisal guidance
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Technology appraisal guidance
TBC
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome
Diagnostics guidance
19 December 2024
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Technology appraisal guidance
30 April 2025
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Technology appraisal guidance
TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]
Technology appraisal guidance
23 April 2025
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Technology appraisal guidance
TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
Technology appraisal guidance
TBC
Implanting a baroreceptor stimulation device for resistant hypertension
Interventional procedures guidance
TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]
Technology appraisal guidance
TBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459
Technology appraisal guidance
TBC
Insertion of neo-chordae into the beating heart for mitral regurgitation
Interventional procedures guidance
TBC
Insulin icodec for treating type 2 diabetes [ID6175]
Technology appraisal guidance
TBC
Intermittent urethral catheters for urinary management in adults : Late Stage Assessment
Health technology evaluation
TBC
Intrapartum Care - maternal hyponatremia
NICE guideline
26 March 2025
Intrapartum care - uterotonics for postpartum haemorrhage
NICE guideline
3 December 2024
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention
Interventional procedures guidance
5 February 2025
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Technology appraisal guidance
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Technology appraisal guidance
TBC
Iptacopan for treating complement 3 glomerulopathy ID6283
Technology appraisal guidance
TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981
Technology appraisal guidance
16 July 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
Technology appraisal guidance
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Technology appraisal guidance
TBC
Previous page
1
…
5
6
Current page
7
8
9
…
16
Page
7
of
16
Next page
Results per page
10
25
50
All
Back to top